Are peptides safe? What research says about medicines, cosmetics and research peptides

Peptides are found in cosmetics, supplements, medicines and materials for laboratory research. Are peptides safe? The answer depends on the group and specific application in question.

Below, we explain the differences between the main types of peptides and what is known about their safety in cosmetics, supplements, treatment and laboratory research using peptides as reagents and research materials.

Disclaimer regarding the intended use of products

This article is for informational and educational purposes only. Information concerning scientific research, biological mechanisms, clinical applications and medicinal products refers to published scientific literature and duly authorised medicinal products. It does not define the intended use of products offered by ILABS and should not be interpreted as information suggesting that these products may be used in humans or animals.

The research findings cited concern substances, experimental models or duly authorised medicinal products described in the literature. They do not describe the effects, efficacy or safety of commercial ILABS products.

A substance discussed in scientific literature or used in authorised medicinal products sharing a name with a research material offered by ILABS does not mean that their intended use, pharmaceutical quality, method of use or legal status are the same.

Types of peptides and their applications

To answer whether peptides are safe, we first need to distinguish which peptides we are discussing. The term itself covers compounds used for very different purposes.

Peptides are short chains of amino acids, the same compounds that make up proteins. In the body, they can act as signalling molecules and participate in processes such as the regulation of hormones, metabolism, immune responses and repair. Their properties depend on the sequence, length and structure of the molecule, so not all peptides act in the same way.

Several main groups can be distinguished by their application:

• Peptides derived from food and used in supplements – most commonly shorter protein fragments, such as collagen hydrolysates.
• Cosmetic peptides – ingredients in products applied to the skin, used in skincare and anti-ageing products, among other applications.
• Therapeutic peptides – active ingredients in medicines, such as insulin or GLP-1 analogues.
• Research peptides – compounds analysed under laboratory conditions to investigate specific biological mechanisms, including those related to tissue regeneration, metabolism and inflammatory processes.

Each of these groups has different applications and a different body of evidence regarding safety. In the following sections, we examine them separately.

We describe the structure, properties and uses of these compounds in more detail in the article “What are peptides and why are they important in laboratory research?”.

Peptides in supplements

In supplements, peptides are most commonly present as shorter protein fragments, primarily collagen hydrolysates. The answer to whether peptides are safe in supplements depends on factors such as the type of ingredient, its quality and how it is used.

Oral supplementation with hydrolysed collagen is generally well tolerated, and its safety is supported by human studies and many years of use. In practice, product quality, the source of the raw material and potential allergens matter more than the presence of peptides alone.

Peptides in cosmetics

Are peptides safe in cosmetics? Many peptides used in cosmetic products generally have a good safety profile when used as intended. They are most commonly found in creams and serums designed for anti-ageing, skin regeneration and improving the appearance of the skin.

Their effects depend on the type of peptide. Signalling peptides, such as Palmitoyl Pentapeptide-4 and Palmitoyl Tripeptide-1, support processes related to collagen synthesis and skin remodelling. Copper peptides, primarily Copper Tripeptide-1 (GHK-Cu), are used in regenerating products. Acetyl Hexapeptide-8, in turn, is used mainly in cosmetics targeting expression lines.

Data on tolerability and the safety of topical use are available for many popular peptides. In assessments covering several dozen peptides and proteins used in cosmetics, most were considered safe at the concentrations and under the conditions of use assessed. Many of these molecules also penetrate the stratum corneum poorly, so their effects and exposure are primarily localised to the application site.

In the European Union, a cosmetic product made available on the market must be safe for human health under normal or reasonably foreseeable conditions of use. Before a cosmetic product is placed on the market, the responsible person must ensure that a safety assessment is carried out and a cosmetic product safety report is prepared in accordance with applicable regulations.

For creams or serums containing peptides, the safety assessment covers the finished product and its entire formulation, rather than just a single ingredient. This does not mean that an adverse reaction or irritation can be completely ruled out for every individual.

A reaction may be associated with a particular peptide or with other ingredients in the product, such as fragrances, preservatives or acids. If burning, itching, swelling or persistent redness occurs, stop using the product and follow the information and warnings provided by the manufacturer.

Peptides in medicines and their safety

Peptides have long been used as active ingredients in medicines. Insulin is the best-known example, but this group also includes semaglutide and other GLP-1 receptor agonists, desmopressin and certain hormonal medicines. Insulin therapy has been used for over a hundred years, and the development of peptide medicines has significantly expanded their use in medicine.

Approved peptide medicines have undergone a benefit–risk assessment for specific indications, and their adverse effects and contraindications continue to be monitored after marketing authorisation. Before they are used in treatment, they undergo clinical trials assessing their efficacy, dosage and adverse effects. After they reach the market, their safety continues to be monitored, allowing information to be updated on rarer problems that emerge only with wider use. (EMA)

Insulin, used to treat diabetes for over a hundred years, is a good example. It is known how to adjust its dose, monitor the effectiveness of treatment and reduce the risk of hypoglycaemia, or excessively low blood glucose. These well-established principles of use are what allow insulin therapy under medical supervision to be conducted safely for many years.

The situation is similar for newer peptide medicines, such as semaglutide and other GLP-1 receptor agonists. Their safety has been assessed in large clinical trials, and their most common adverse effects are well known. These primarily include nausea and other gastrointestinal symptoms, which occur more frequently at the start of treatment or when the dose is increased.

As Harvard Health also summarises, good safety data are available for approved peptide medicines.

The answer to whether peptides are safe as active ingredients in medicines depends on the specific product and the person taking it. Authorised peptide medicines can be used safely when treatment is appropriately selected and conducted under medical supervision. Such treatment should not be started, stopped or modified independently.

Research peptides and their safety

For substances such as BPC-157, TB-500, KPV or MOTS-C, whether peptides are safe for human use remains insufficiently established by clinical research. Most available data come from laboratory and animal studies, rather than large human studies. RUO research materials are not intended for use in humans or animals.

A review published in 2026 concerning BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu analysed 565 publications. More than two-thirds of the studies were conducted exclusively in animals. Human studies were much less common and often had methodological limitations. (UCLA Health)

Such studies can provide information about mechanisms and effects observed in specific experimental models, but they do not allow these findings to be automatically extrapolated to humans. The absence of reported problems may therefore reflect limited data rather than established safety. (Harvard Health)

The quality of the product itself is a separate issue. In laboratory research, factors such as purity, confirmation of compound identity and the presence of impurities are important. The FDA also highlights synthesis by-products and aggregates, which may affect the body’s response. (FDA)

Research peptides cannot be considered safe for human use simply because preclinical findings are promising. Until a substance has undergone appropriate clinical trials and been assessed for a specific application, the available findings cannot confirm its safety for that application.

In practice, this means that research peptides should not be self-administered, injected or used for therapeutic, regenerative or “wellness” purposes. These products are intended for laboratory research, not for use in humans or animals.

We also discuss the differences between laboratory, animal and clinical findings in the article “Peptides and joint regeneration – BPC-157, TB-500 and other peptides in light of research”.

Research Use Only: what does it mean in practice?

The Research Use Only (RUO) label indicates that a product is intended exclusively for laboratory research. It may be used as a reagent or test material, for example to analyse a peptide’s properties, study its biological activity, work with cellular models or develop analytical methods.

In this application, the characteristics of the material itself are particularly important. A laboratory should know which substance it is working with, so confirmed peptide identity, purity, stability and batch-specific documentation are essential. This information makes it possible to plan an experiment properly and later reproduce its conditions.

However, RUO is not a medicinal product category, nor does it determine a product’s legal status on its own. This label does not confirm safety for human use and does not mean that a substance has undergone clinical trials. A peptide may be well characterised and highly pure as a laboratory material while still lacking established clinical safety.

RUO products are not intended for use in humans or animals, including ingestion, injection or use for therapeutic, regenerative or “wellness” purposes. Their proper application is research conducted in accordance with laboratory procedures.

Is studying peptides in the laboratory safe?

The risks associated with working with research peptides can be reduced by following laboratory procedures appropriate to the specific substance, its classification, safety documentation and physicochemical properties. However, there is no single set of conditions suitable for all peptides. They differ in stability, solubility and susceptibility to degradation.

Synthetic peptides should be handled by people with appropriate technical training and in accordance with the product’s safety data sheet. This is particularly important for new compounds whose chemical and toxicological properties may not yet be fully described.

Storage affects sample quality

Many synthetic peptides are supplied as a lyophilisate, a dry material from which water has been removed. This form is usually more stable than a prepared solution.

For many peptides, manufacturers recommend long-term storage of the lyophilisate at around -20°C or below, with limited exposure to moisture and light. Before opening a chilled vial, it is advisable to allow it to reach room temperature. This reduces moisture condensation inside the container. Solutions are usually less stable, so repeated freezing and thawing of the same sample is also avoided. (Sigma-Aldrich)

However, these conditions are not universal for every sequence. Some peptides are more susceptible to oxidation or other chemical changes, so the documentation for the specific product always takes precedence.

Documentation and quality control

When working with research materials, a laboratory should be able to determine what a sample contains and what its basic characteristics are. The batch number, sequence or compound name, stated purity, molecular mass, storage conditions and analytical quality control results are therefore important.

For synthetic peptides, HPLC and mass spectrometry (MS) are often used for this purpose. These methods provide different types of information.

HPLC separates the components of a sample and allows the proportion of the main component to be assessed relative to other detected substances. It is widely used to check peptide purity and monitor impurities formed during synthesis or storage.

Mass spectrometry, in turn, allows the mass of the molecule being analysed to be checked. It can therefore confirm whether the main component of a sample corresponds to the expected peptide, and in more extensive analyses it also helps identify impurities.

This is an important distinction. A result of 99% in HPLC analysis indicates the chromatographic purity of a sample, but does not, on its own, confirm the peptide’s identity. This is why HPLC and MS are often used together: one method helps assess purity, while the other confirms which molecule is present. This combination is also used in professional quality control methods for synthetic peptides.

Working safely with a research peptide therefore involves more than a single parameter or analytical result. Appropriate working conditions, maintaining material stability and confidence in its identity and quality all matter. Only then can the sample be expected not only to be suitable for a given experiment, but also to yield reliable and reproducible results.

Summary

The answer to the question “are peptides safe?” depends on their type and application. Peptides used in cosmetics generally have a good safety profile when used as intended. Protein hydrolysates found in supplements, such as collagen peptides, are generally well tolerated. Approved peptide medicines can also be used safely if treatment is appropriately selected and conducted under medical supervision.

Research peptides offered as Research Use Only belong to a different category. They are materials intended for laboratory research, and their quality is assessed primarily in terms of identity, purity, stability and analytical documentation. For many such peptides, knowledge comes mainly from laboratory studies and animal models, while human data remain limited.

For RUO products, safety therefore primarily means handling the material appropriately under laboratory conditions and maintaining its quality throughout the experiment. A reagent’s analytical characteristics do not constitute an assessment of clinical safety and do not change its intended research use. RUO research materials are not intended for use in humans or animals.

Peptide safety is best discussed with reference to a specific substance and how it is used. This distinction helps separate well-established cosmetic, supplement and therapeutic applications from peptides used as research materials.